| Name | Title | Contact Details |
|---|
GAMΞRSΞ is the home of NFT gaming and the metaverse. Create your 3D identity, enter a world of gaming discovery, create your groups (LFGs), create parties and stay social with friends! Stay up-to-date with our live feed and never miss a drop again!
FTS International is a leading independent provider of well stimulation services for the oil and gas industry in the United States. The company also has several international joint venture projects in progress. Exploration and production companies use our services primarily to enhance their recovery rates from wells drilled in shale and other unconventional reservoirs. We continue to focus on more environmentally friendly ways to do business - developing vital assets and promoting energy independence, while protecting natural resources.
Pack N Ship Etc is a Sullivan, MO-based company in the Business Services sector.
E Project International Inc is a Phoenix, AZ-based company in the Business Services sector.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN